An Open-label, Randomized, Single-dose, 2-sequence, 4-period, Cross-over, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-331 in Healthy Adult Volunteers
Latest Information Update: 12 Jun 2023
At a glance
- Drugs CKD 331 (Primary)
- Indications Dyslipidaemias; Hypertension
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 07 Jun 2023 Status changed from not yet recruiting to completed.
- 27 Apr 2022 New trial record